Ignite Creation Date:
2024-05-06 @ 2:22 AM
Last Modification Date:
2024-10-26 @ 11:17 AM
Study NCT ID:
NCT02034981
Status:
COMPLETED
Last Update Posted:
2024-02-28
First Post:
2013-10-16
Brief Title:
Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK MET or ROS1
Sponsor:
UNICANCER
Organization:
UNICANCER